Grayzel David S.
- SEC CIK
- 0001732786
No open-market purchases or sales filed in the past year.
Current role at each company
- QTTB Q32 Bio Inc.Directoras of Jul 21, 2026
- JBIO Jade Biosciences, Inc.Directoras of Jun 7, 2024
- SURF Surface Oncology, Inc.Directoras of Sep 8, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Grayzel David S. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
JBIO Jade Biosciences, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2024 (view filing) | Apr 9 | 2 days | Grayzel David S.Director | SSale | −11.9K | $28.15 | −$334.5K | −45.0%14.5K after | |
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Grayzel David S.Director | PPurchase | +535.7K | $14.00 | +$7.50M | +20.9%3.10M after |